NCT00454987View on ClinicalTrials.gov

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

May 16, 2007

Primary Completion Date

October 12, 2007

Study Completion Date

October 12, 2007

Conditions
Haemophilus Influenzae Type bNeisseria MeningitidisNeisseria Meningitidis-Haemophilus Influenzae Type b Vaccine
Interventions
BIOLOGICAL

Menitorix

Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.

BIOLOGICAL

Infanrix IPV

Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.

Trial Locations (9)

85-021

GSK Investigational Site, Bydgoszcz

80-394

GSK Investigational Site, Gdansk

25-711

GSK Investigational Site, Kielce

31-202

GSK Investigational Site, Krakow

61-709

GSK Investigational Site, Poznan

41-103

GSK Investigational Site, Siemianowice Śląskie

55-100

GSK Investigational Site, Trzebnica

21-010

GSK Investigational Site, Łęczna

OX3 7LJ

GSK Investigational Site, Oxford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY